175 related articles for article (PubMed ID: 29768143)
1. Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.
Gounder MM; Solit DB; Tap WD
N Engl J Med; 2018 May; 378(20):1945-1947. PubMed ID: 29768143
[No Abstract] [Full Text] [Related]
2. A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.
Kumamoto T; Aoki Y; Sonoda T; Yamanishi M; Arakawa A; Sugiyama M; Shirakawa N; Ishimaru S; Saito Y; Maeshima A; Maeda M; Ogawa C
Int J Hematol; 2019 Feb; 109(2):228-232. PubMed ID: 30361829
[TBL] [Abstract][Full Text] [Related]
3. Targeting MEK in a Translational Model of Histiocytic Sarcoma.
Takada M; Hix JML; Corner S; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
Mol Cancer Ther; 2018 Nov; 17(11):2439-2450. PubMed ID: 30135215
[TBL] [Abstract][Full Text] [Related]
4. Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.
Andritsos LA; Grieselhuber NR; Anghelina M; Rogers KA; Roychowdhury S; Reeser JW; Timmers CD; Freud AG; Blachly JS; Lucas DM; Lozanski G; Jones JA; Williams K; Oakes C; Jones D; Grever MR
Leuk Lymphoma; 2018 Apr; 59(4):1008-1011. PubMed ID: 28918710
[No Abstract] [Full Text] [Related]
5. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.
Lian T; Li C; Wang H
Cancer Treat Rev; 2019 Dec; 81():101907. PubMed ID: 31715422
[TBL] [Abstract][Full Text] [Related]
6. Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
Azorsa DO; Lee DW; Wai DH; Bista R; Patel AR; Aleem E; Henry MM; Arceci RJ
Pediatr Blood Cancer; 2018 Sep; 65(9):e27237. PubMed ID: 29768711
[TBL] [Abstract][Full Text] [Related]
7. Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.
Krebs FS; Moura B; Missiaglia E; Aedo-Lopez V; Michielin O; Tsantoulis P; Bisig B; Trimech M; Zoete V; Homicsko K
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901951
[TBL] [Abstract][Full Text] [Related]
8. Trametinib (GSK1120212) in the treatment of melanoma.
Salama AK; Kim KB
Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
[TBL] [Abstract][Full Text] [Related]
9. Promises from trametinib in RAF active tumors.
Sausville EA
N Engl J Med; 2012 Jul; 367(2):171-2. PubMed ID: 22663012
[No Abstract] [Full Text] [Related]
10. Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-α production and endotoxin shock.
Shi-Lin D; Yuan X; Zhan S; Luo-Jia T; Chao-Yang T
Biochem Biophys Res Commun; 2015 Mar; 458(3):667-673. PubMed ID: 25684183
[TBL] [Abstract][Full Text] [Related]
11. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.
Gannon HS; Kaplan N; Tsherniak A; Vazquez F; Weir BA; Hahn WC; Meyerson M
Mol Cancer Res; 2016 Feb; 14(2):207-15. PubMed ID: 26582713
[TBL] [Abstract][Full Text] [Related]
12. Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
[TBL] [Abstract][Full Text] [Related]
13. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.
Roskoski R
Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260
[TBL] [Abstract][Full Text] [Related]
14. Trametinib.
Zeiser R
Recent Results Cancer Res; 2014; 201():241-8. PubMed ID: 24756797
[TBL] [Abstract][Full Text] [Related]
15. Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation.
Hu B; Patel JL; Tao R; Cannon RB; Monroe M; Goyal G
J Natl Compr Canc Netw; 2022 Mar; 20(6):618-621. PubMed ID: 35325867
[TBL] [Abstract][Full Text] [Related]
16. Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib.
Zhu J; Li C; Yang H; Guo X; Huang T; Han W
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245216
[TBL] [Abstract][Full Text] [Related]
17. Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion.
Lorillon G; Jouenne F; Baroudjian B; de Margerie-Mellon C; Vercellino L; Meignin V; Lebbe C; Vassallo R; Mourah S; Tazi A
Am J Respir Crit Care Med; 2018 Sep; 198(5):675-678. PubMed ID: 29694792
[No Abstract] [Full Text] [Related]
18. Trametinib in metastatic melanoma.
Chopra N; Nathan PD
Expert Rev Anticancer Ther; 2015; 15(7):749-60. PubMed ID: 26107021
[TBL] [Abstract][Full Text] [Related]
19. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.
Andrews MC; Behren A; Chionh F; Mariadason J; Vella LJ; Do H; Dobrovic A; Tebbutt N; Cebon J
J Clin Oncol; 2013 Dec; 31(35):e448-51. PubMed ID: 24190114
[No Abstract] [Full Text] [Related]
20. Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent.
Leonard JT; Raess PW; Dunlap J; Hayes-Lattin B; Tyner JW; Traer E
J Hematol Oncol; 2016 Mar; 9():31. PubMed ID: 27036514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]